Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer

Cancer

Volumn 116, Issue 6, 2010, Pages 1476-1484

  Sarosy, Gisele A ^a   Hussain, Mahrukh M ^a   Seiden, Michael V ^b,c   Fuller, Arlan F ^b   Nikrui, Najmosama ^b   Goodman, Annekathryn ^b   Minasian, Lori ^a   Reed, Eddie ^a,d   Steinberg, Seth M ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Antineoplastic combined chemotherapy protocols; Cisplatin; Cyclophosphamide; Drug dose response relation; Filgrastim; Ovarian neoplasms; Paclitaxel

Indexed keywords

AMITRIPTYLINE; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; GABAPENTIN; ONDANSETRON; OXYCODONE; PACLITAXEL; PARACETAMOL; PROCHLORPERAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SERTRALINE;

ADVANCED CANCER; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE PAIN; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GILBERT DISEASE; HEARING IMPAIRMENT; HUMAN; HYPERBILIRUBINEMIA; HYPOMAGNESEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; TREATMENT OUTCOME;

EID: 77949375558     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24861     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol. 2007;34(2 suppl 2):S1-S15.
3. Thigpen T. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. Semin Oncol. 2006;33(2 suppl 6):S26-S32.
4. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
5. Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. The role of maintenance therapy and novel taxanes in ovarian cancer. Gynecol Oncol. 2006;102:218-225.
6. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33(2 suppl 6):S3-S11.
7. Cadron I, Leunen K, Amant F, Van Gorp T, Neven P, Vergote I. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol. 2007;106:354-361.
8. Vasey PA. "Dose dense" chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2005;15(suppl 3):226-232.
9. van der Burg ME, van der Gaast A, Vergote I, et al. What is the role of dose-dense therapy? Int J Gynecol Cancer. 2005;15(suppl 3):233-240.
10. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995;13:1589-1599.
11. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, openlabel, randomised controlled trial. Lancet. 2009;374:1331-1338.
12. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663-1671.
13. Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr. 1993;15:83-88.
14. Ragazzi E, D'Ancona S, Berti E, Carrara M. Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex. Anticancer Res. 2002;22:2783-2788.
15. Engblom P, Rantanen V, Kulmala J, Helenius H, Grenman S. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer. 1999;79:286-292.
16. Reed E, Kohn EC, Sarosy G, et al. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol. 1995;22(3 suppl 6):90-96.
17. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5(suppl 6):S3-S6.
18. Vanhoefer U, Harstrick A, Wilke H, et al. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer. 1995;31A:92-97.
19. Sarosy G, Kohn E, Stone DA, et al. Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol. 1992;10:1165-1170.
20. Kohn EC, Sarosy GA, Davis P, et al. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol. 1996;62:181-191.
21. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
22. Sehouli J, Stengel D, Mustea A, et al. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol. 2008;61:243-250.
23. Kristensen GB, Vergote I, Stuart G, et al. First-line treatment of ovarian cancer FIGO stages IIB-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer. 2003;13(suppl 2):172-177.
24. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106-115.